Compare
Cerenome, Inc. vs Lucid Diagnostics Inc. vs Intelligent Bio Solutions Inc. vs Encision Inc
| Latest fiscal year | Cerenome, Inc. CNSY | Lucid Diagnostics Inc. LUCD | Intelligent Bio Solutions Inc. INBS | Encision Inc ECIALast annual report: year ended 2025-03-31 |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-03-31 |
| Revenue | $5.21M | $4.71M | $4.22M | $6.56M |
| Revenue growth (YoY) | -10.5% | +8.3% | +38.1% | -0.5% |
| Gross margin | n/a | -41.7% (computed) | 48.6% | 53.6% |
| Operating margin | -293.5% | n/m | -299.1% | -2.6% |
| Net margin | -429.4% | n/m | -294.9% | -3.4% |
| Net income | -$22.39M | -$58.01M | -$12.43M | -$220.2K |
| EPS (Diluted) | -$0.29 | n/a | -$8.44 | -$0.02 |
| Operating cash flow | -$20.77M | -$46.48M | -$11.93M | -$54.9K |
| Free cash flow | -$20.84M | -$46.68M | -$12.05M | -$109.4K |
| Cash & equivalents | $4.26M | n/a | $3.99M | $257.4K |
| Total assets | $16.32M | $40.45M | $11.94M | $3.67M |
| Total liabilities | $12.33M | $29.51M | $6.65M | $2.02M |
| Shareholders' equity | $4.00M | $10.94M | $5.51M | $1.65M |
| Return on year-end equity | -560.2% | -530.4% | -225.6% | -13.3% |
| Shares outstanding | 138.68M | 131.10M | 2.91M | 11.88M |
Revenue, most recent five fiscal years
| Fiscal year | Cerenome, Inc. | Lucid Diagnostics Inc. | Intelligent Bio Solutions Inc. | Encision Inc |
|---|---|---|---|---|
| Latest | $5.21M Ended 2025-12-31 | $4.71M Ended 2025-12-31 | $4.22M Ended 2026-06-30 | $6.56M Ended 2025-03-31 |
| 1 year earlier | $5.82M Ended 2024-12-31 | $4.35M Ended 2024-12-31 | $3.05M Ended 2025-06-30 | $6.59M Ended 2024-03-31 |
| 2 years earlier | $4.91M Ended 2023-12-31 | $2.43M Ended 2023-12-31 | $3.11M Ended 2024-06-30 | $7.35M Ended 2023-03-31 |
| 3 years earlier | n/a | $377.0K Ended 2022-12-31 | $1.26M Ended 2023-06-30 | $7.67M Ended 2022-03-31 |
| 4 years earlier | n/a | $500.0K Ended 2021-12-31 | $437.1K Ended 2022-06-30 | $7.54M Ended 2021-03-31 |